The FDA cleared a technique called analogous fat transfer for Andrew Technologies’ HydraSolve liposuction procedure.
The technique allows surgeons to reinject a patient’s own fat, gathered during the HydraSolve liposuction procedure.
HydraSolve uses a saline solution to liquefy fat tissue, a process called disaggregation. Analogous fat transfer maintains that fat tissue for injection into different parts of the body.
The Irvine, Calif.-based medical technology company is touting the FDA’s 510(k) clearance as a first for this use. Andrew Technologies was founded in 2007 and has been primarily funded by the venture capital firms WFD Ventures and NJTC Venture Fund, according to a company statement.
"We are extremely pleased to take a leading role in providing technology for autologous fat grafting that we believe can improve the process for the surgeon and the outcome for the patient," founder and CSO Mark Andrew said in prepared remarks.
